Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice

References

• Barrios V, Escobar C, Echarri R, de Alvaro F. New therapeutic progress in cardiorenal protection of the hypertensive patient with a focus on olmesartan. In: Hot Topics in Hypertension Vol. 2, Issue 8. Volpe M (Ed.). FBCommunication, Modena, Italy, 1–24 (2009).
   Google Scholar
• Volpe M. Angiotensin II: an amplifier of cardiovascular risk. Curr. Hypertens. Rep.6, 247–248 (2004).
   PubMed Web of Science ®Google Scholar
• Volpe M, Musumeci B, De Paolis P, Savoia C, Morganti A. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J. Hypertens.21, 1429–1443 (2003).
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin–angiotensin system and cardiovascular risk. Lancet369, 1208–1219 (2007).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. Expert Opin. Pharmacother.9, 129–136 (2008).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358, 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362, 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension45, 198–202 (2005).
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Ruggenenti P, Perna A et al. Continuum of renoprotection with losartan at all stages of Type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J. Am. Soc. Nephrol.15, 3117–3125 (2004).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med.351, 1952–1961 (2004).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25, 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Bertomeu V, Murga N, de Pablo C, Calderón A. Sex differences in the hypertensive population with chronic ischemic heart disease. J. Clin. Hypertens. (Greenwich)10, 779–786 (2008).
   Web of Science ®Google Scholar
• Barrios V, Escobar C, Divisón JA, Medialdea F. Clinical experience with a low dose fixed combination of perindopril plus indapamide in a primary-care setting: the PRETEND study. Therapy4, 677–683 (2007).
   Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med.342, 1887–1892 (2000).
   PubMed Web of Science ®Google Scholar
• Steg PG, Lopez-Sendon J, Lopez de Sa E et al. External validity of clinical trials in acute myocardial infarction. Arch. Intern. Med.167, 68–73 (2007).
   PubMedGoogle Scholar
• Barrios V, Escobar C, Bertomeu V, Murga N, de Pablo C, Calderón A. Risk factor control in the hypertensive patients with chronic ischemic heart disease attended in cardiologic outpatient clinics. The CINHTIA study. Rev. Clin. Esp.208, 400–404 (2008).
   PubMed Web of Science ®Google Scholar
• Neutel JM. Choosing among renin–angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Curr. Med. Res. Opin.26, 213–222 (2010).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Prieto L, Herranz I. Adverse events in clinical trials: is a new approach needed? Lancet372, 535–536 (2008).
   PubMed Web of Science ®Google Scholar
• Cleland JG. Role of angiotensin receptor blockers in the treatment of chronic heart failure: what do the clinical practice guidelines say? Rev. Esp. Cardiol.6(Suppl. C), 58–72 (2006).
   Google Scholar
• Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Intern. Med.148, 16–29 (2008).
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med.115, 41–46 (2003).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderón A, Echarri R, Barrios S, Navarro-Cid J. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study. J. Renin Angiotensin Aldosterone Syst.10, 168–173 (2009).
   PubMed Web of Science ®Google Scholar